Abortion Pill Maker Asks Supreme Court to Stop Mail Ban

A legal fight over abortion access surged back to the US supreme court on Saturday, with the maker of mifepristone asking the justices to stop a new barrier to mail-order prescribing.

Danco Laboratories filed an emergency appeal after the fifth US circuit court of appeals temporarily revived a requirement that patients receive an in-person exam before the medication can be prescribed. That move blocks telemedicine providers from prescribing the drug by mail, at least for now, and marks another sharp turn in a case that keeps reshaping access through the courts rather than through legislatures or health agencies.

The latest appeal puts a basic question in front of the justices: who decides how patients can access a closely watched medication — doctors and regulators, or judges responding to state challenges?

The challenge came from Louisiana, according to reports, and it landed with unusual speed. Danco asked the high court to freeze the lower court's decision just hours after the appeals court acted. The urgency reflects what is at stake: telemedicine has become a critical path for patients seeking reproductive healthcare, especially in places where travel, clinic access, or state law already limit options.

The case also shows how abortion policy now moves through overlapping legal channels, where a single ruling can quickly alter care nationwide. Mifepristone sits at the center of that struggle because it affects not just abortion access, but the reach of telemedicine itself. When courts change prescribing rules, providers must adjust immediately, and patients often absorb the disruption first.

What happens next depends on how quickly the supreme court responds and whether it treats the lower court order as a temporary procedural step or a broader threat to established access. Either way, the decision will matter far beyond one drugmaker. It could shape how far states can push restrictions into medical practice, and whether mail-based care remains a viable option in one of the country's most contested areas of health policy.